KOL kliniske forsøg i Alabama
21 studier for KOL søger deltagere på steder i Alabama.
Byer i Alabama
Officiel studietekst (engelsk)
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Research Site, Cullman
- Research Site, Mobile
RekruttererFase 3
Alder 40 til 80 · Alle køn · Opdateret 2. okt. 2026 · NCT06283966Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- University of Alabama at Birmingham- Site Number : 8400003, Birmingham
- Pulmonary Associates - Mobile- Site Number : 8400151, Mobile
RekruttererFase 3
Alder 40 til 80 · Alle køn · Opdateret 1. okt. 2026 · NCT07190222A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
- University of Alabama at Birmingham, Birmingham
RekruttererFase 2
Alder 40 til 75 · Alle køn · Opdateret 25. sep. 2026 · NCT07759245A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
- University of Alabama at Birmingham - School of Medicine- Site Number : 8400003, Birmingham
RekruttererFase 4
Alder 40 til 85 · Alle køn · Opdateret 22. sep. 2026 · NCT07053423A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- Research Site, Birmingham
RekruttererFase 2
Alder 40 og opefter · Alle køn · Opdateret 9. sep. 2026 · NCT07082738Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
- University of Alabama, Birmingham
RekruttererFase 2
Alder 40 og opefter · Alle køn · Opdateret 4. sep. 2026 · NCT07059091A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
- Research Site, Cullman
RekruttererFase 3
Alder 40 til 80 · Alle køn · Opdateret 3. sep. 2026 · NCT06878261A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
- Research Site, Foley
- Research Site, Mobile
- Research Site, Sheffield
RekruttererFase 3
Alder 40 til 80 · Alle køn · Opdateret 3. sep. 2026 · NCT06883305A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease
- University of Alabama at Birmingham, Birmingham
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 2. sep. 2026 · NCT06603246A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
- University of Alabama at Birmingham Lung Health Center, Birmingham
- SEC Clinical Research, Dothan
- Pulmonary Associates of Mobile, P.C., Mobile
RekruttererFase 2/3
Alder 35 til 80 · Alle køn · Opdateret 31. aug. 2026 · NCT07363694A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
- GC2501 Study Site 106, Birmingham
RekruttererFase 3
Alder 18 til 80 · Alle køn · Opdateret 11. aug. 2026 · NCT07555483Improving Patient-Centered Care for Underserved Older African American Patients With Cardiovascular Comorbidities
- Cooper Green Mercy Hospital, Birmingham
RekruttererObservationsstudie
Alder 50 til 99 · Alle køn · Opdateret 6. aug. 2026 · NCT07748858Multi-Center Clean Air Randomized Controlled Trial in COPD
- University of Alabama, Lung Health Center, Birmingham
RekruttererFase 3
Alder 40 og opefter · Alle køn · Opdateret 31. jul. 2026 · NCT06376994Closed Loop Oxygen Control in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Nasal High Flow in the Hospital
- The University of Alabama at Birmingham, Birmingham
Rekrutterer
Alder 22 og opefter · Alle køn · Opdateret 23. jun. 2026 · NCT07222410SPIROMICS Study of Early COPD Progression (SOURCE)
- University of Alabama at Birmingham, Birmingham
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 30 til 55 · Alle køn · Opdateret 3. jun. 2026 · NCT05033990Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD
- University of Alabama-Birmingham Hospital - UAB Lung Health Center, Birmingham
Rekrutterer
Alder 40 til 80 · Alle køn · Opdateret 28. apr. 2026 · NCT07051707Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3
- University of Alabama at Birmingham, Birmingham
Rekrutterer
Alder 40 til 84 · Alle køn · Opdateret 24. apr. 2026 · NCT06891755Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
- GSK Investigational Site, Sheffield
RekruttererFase 3
Alder 40 til 80 · Alle køn · Opdateret 9. apr. 2026 · NCT06961214PiMZ Longitudinal Cohort (PiMZ Logic)
- University of Alabama at Birmingham, Birmingham
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 16. jan. 2026 · NCT06505603Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency
- University of Alabama at Birmingham, Birmingham
RekruttererFase 4
Alder 19 og opefter · Alle køn · Opdateret 10. nov. 2025 · NCT07135427myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home
- UAB School of Medicine/Lung Health Center, Birmingham
Rekrutterer
Alder 30 og opefter · Alle køn · Opdateret 6. feb. 2025 · NCT05204888Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.